{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:18:59Z","timestamp":1780568339719,"version":"3.54.1"},"reference-count":90,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["TA 1154\/1-2 and TA 1154\/2-2."],"award-info":[{"award-number":["TA 1154\/1-2 and TA 1154\/2-2."]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Endocrinology"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Cancer negatively impacts bone health through various mechanisms, including treatment-induced bone loss and malignant bone lesions, often leading to increased fracture risk and higher morbidity and mortality. Antiresorptive agents (bisphosphonates and denosumab) are the current standard of care to reduce the risk of skeletal-related events and prevent treatment-related fragility fractures in patients with cancer. While there is strong evidence to support their benefits in cancer, there is potential room for further reduction in the risk of pathologic and fragility fractures. This narrative review explores the potential role and theoretical concerns regarding the use of osteoanabolic agents in cancer. We also discuss management challenges, such as recurrent pathologic fractures, fragility fractures, and osteonecrosis of the jaw that may arise in clinical practice, prompting consideration of the use of osteoanabolic agents in patients with a history of cancer. Preclinical studies have shown conflicting outcomes regarding the effects on cancer with parathyroid hormone treatment, but promising results with the use of anti-sclerostin antibody in cancer models. Definitive conclusions cannot be drawn from available preclinical and clinical data. Theoretical risks exist for both cancer survivors and patients with advanced cancer in the bone. Therefore, the risk-benefit ratio should be carefully considered when evaluating the use of an osteoanabolic agent in the cancer context.<\/jats:p>","DOI":"10.1177\/20420188251367252","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T05:23:27Z","timestamp":1756790607000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Bone health in cancer: perspective on the use of osteoanabolic agents"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9277-4171","authenticated-orcid":false,"given":"Tariq","family":"Chukir","sequence":"first","affiliation":[{"name":"Medical Education Department, Weill Cornell Medicine\u2014Qatar, Doha, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Taipaleenm\u00e4eki","sequence":"additional","affiliation":[{"name":"Institute of Musculoskeletal Medicine, University Hospital, LMU Munich, Munich, Germany"},{"name":"Musculoskeletal University Center Munich, University Hospital, LMU Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Cheung","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeez","family":"Farooki","sequence":"additional","affiliation":[{"name":"Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 530 E 74th Street, New York, NY 10021, USA"},{"name":"Weill Cornell Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,9]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0196"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2015.1020484"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041943"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000059281.67667.97"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30715-5"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3744"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0215"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13834"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02647"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0576"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.5069"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01812-9"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200162"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS10616"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6716"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06690-1"},{"key":"e_1_3_4_18_2","volume-title":"PD-1 blockade induces musculoskeletal toxicities through T cell expansion","author":"Joseph G.","year":"2024","unstructured":"Joseph G. PD-1 blockade induces musculoskeletal toxicities through T cell expansion. Poster presented at the ASBMR 2024 [poster presentation 1010], Toronto, Ontario, Canada, 2024."},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.2.328"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.965258"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/hp.2000.6698"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930230311"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100597"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.12.016"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143764"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.22550"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050434"},{"issue":"2","key":"e_1_3_4_28_2","first-page":"249","article-title":"Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate","volume":"3","author":"Melchior SW","year":"1997","unstructured":"Melchior SW, Corey E, Ellis WJ, et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997; 3(2): 249\u2013256.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.12.003"},{"issue":"20","key":"e_1_3_4_30_2","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman RE.","year":"2006","unstructured":"Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12(20 Pt 2): 6243s\u20136249s.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2009.01135.x"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113317"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.620574"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2019.05.013"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13645"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.4614"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.08.019"},{"key":"e_1_3_4_38_2","unstructured":"FDA. Zometa prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/021223s028lbl.pdf (2014 accessed 17 February 2025)."},{"key":"e_1_3_4_39_2","unstructured":"FDA. Prolia prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/125320s186lbl.pdf (2018 accessed 17 February 2025)."},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11501"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.091"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23529"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101"},{"issue":"10","key":"e_1_3_4_44_2","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O\u2019Carrigan B","year":"2017","unstructured":"O\u2019Carrigan B, Wong MH, Willson ML, et al. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2017; 10(10): CD003474.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.08.002"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.11.008"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-023-03764-w"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2022.101582"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.1.21"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.8195"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-017-0817-8"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-852459"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1703"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0615-3"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27342"},{"issue":"12","key":"e_1_3_4_56_2","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar R","year":"2017","unstructured":"Mhaskar R, Kumar A, Miladinovic B, et al. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev 2017; 12(12): CD003188.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25919"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-773341"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.152"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI43414"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.90874"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.157390"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19102920"},{"key":"e_1_3_4_64_2","author":"Ludington B.","year":"2024","unstructured":"Ludington B. Intermittent abaloparatide treatment stimulates bone formation without affecting breast cancer metastasis. Poster presented at the ASBMR 2024 [poster presentation 1135], Toronto, Ontario, Canada, 2024.","journal-title":"Intermittent abaloparatide treatment stimulates bone formation without affecting breast cancer metastasis"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13766"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11913-7"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.125543"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01697-4"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.3.1.561"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.04.001"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607948"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005361"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02192"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61120-5"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10512"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31613-6"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz278"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziae091"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp266"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10195-023-00715-5"},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.4158\/GL-2020-0524SUPPL"},{"key":"e_1_3_4_83_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4719"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4726"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70106-2"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60856-9"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2021.02.240"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.238"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.otsr.2018.07.015"},{"issue":"3","key":"e_1_3_4_90_2","article-title":"Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence?","volume":"53","author":"Reddy SV","year":"2012","unstructured":"Reddy SV, Gupta SK. Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence? Singapore Med J 2012; 53(3): e52\u2013e54.","journal-title":"Singapore Med J"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1246"}],"container-title":["Therapeutic Advances in Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251367252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420188251367252","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420188251367252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:36:59Z","timestamp":1777592219000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420188251367252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":90,"alternative-id":["10.1177\/20420188251367252"],"URL":"https:\/\/doi.org\/10.1177\/20420188251367252","relation":{},"ISSN":["2042-0188","2042-0196"],"issn-type":[{"value":"2042-0188","type":"print"},{"value":"2042-0196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"20420188251367252"}}